The European Medicines Agency (EMA) said on Tuesday it has extended its probe into Novo Nordisk’s diabetes drug Ozempic and weight-loss treatment Saxenda following two reports of suicidal thoughts to include other drugs in the same class. The agency began its review on July…

Read Full Article (External Site)